#Haematology #oncology #Talvey #Scotland #relapsedandrefractorymultiplemyeloma #multiplemyeloma #SMC #JnJ #ScottishMedicinesConsortium #NHSScotland #antiCD38antibody #bloodcancer #MonumenTAL1study #relapsedmyeloma #bispecifictherapy #MyelomaUK #GPRC5Dexpressingmyelomacells
zurl.co/YbEvY
zurl.co/YbEvY
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma - PharmaTimes
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
pharmatimes.com
June 11, 2026 at 8:14 AM